Developing select technologies
Explore Arch Biopartners platforms, teams and publications
Arch Biopartners is a leader in developing novel drugs to treat acute organ inflammation.
Phase I and Phase II clinical trials (2020-21) have led to the company’s lead drug candidate, LSALT Peptide (Metablok), being the first novel therapeutic to join the Canadian Treatments for COVID-19 trial, a multi-centre adaptive, randomized, open-label, controlled clinical trial involving fifty-five hospitals across Canada.
- In 2019 Arch scientists described a novel mechanism of action for organ inflammation in the journal Cell.
- Arch scientists have identified the enzyme dipeptidase-1 (DPEP1) as a major neutrophil (white blood cell) adhesion receptor in the lungs, kidneys and liver.
- DPEP1 was shown to be the target of LSALT Peptide (Metablok), the Company’s lead drug candidate targeting inflammation in the lungs and kidneys.
Additional programs not currently under development:
The company is led by experienced groups of scientists with an executive, board and advisors with scientific, pharmaceutical, biotechnology and corporate financial experience.
Science and Research Teams
- Metablok is led by Dr. Stephen Robbins Ph. D., Dr. Donna Senger Ph. D. and Jennifer Rahn B Sc., M Sc. at the University of Calgary
- AB569 was led by Dr. Daniel J. Hassett Ph. D. at the University of Cincinnati, College of Medicine until his passing in 2022.
- BORG Peptide is led by Dr. Randall Irvin Ph. D., Dr. Dongyang Li Ph. D. and Dr. Elisabeth Davis Ph. D. at the University of Alberta
- The Treatments for Inflammation team is led by Dr. Daniel Muruve Ph. D., Dr. Justin Macdonald Ph. D., Dr. Paul Beck and Dr. Arthur Lau Ph. D at the University of Calgary
The Arch Biopartners Science Teams have all participated and authored key papers and journal publications as a core part of their ongoing scientific research, discoveries and development.
- Treatments for Inflammation publications surrounding the development of LSALT Peptide (Metablok) as a treatment for inflammation with broad application to prevent organ and tissue injury
- AB569 publications describing AB569 as a novel bactericidal treatment for treatment resistant bacteria and Respiratory Pseudomonas
- BORG Peptide publications discussing a peptide-based biological coating for enhanced corrosion resistance, strength and control of adhesion of bacteria and microbes.
- Brain Tumor Stem Cell Targeting publications describe the development of a peptide-based delivery platform for targeting malignant brain tumors